{"id":9521,"date":"2020-06-09T17:37:27","date_gmt":"2020-06-09T12:07:27","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9521"},"modified":"2023-06-14T11:08:02","modified_gmt":"2023-06-14T05:38:02","slug":"recent-pharma-happenings-for-alnylam-astrazeneca-evotec-astellas","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alnylam-astrazeneca-evotec-astellas","title":{"rendered":"Alnylam\u2019s lumasiran results; AZ\u2019s oncology drug; Astellas Roxadustat; Evotec\u2019s partnership with ABL"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0607420aaa1\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0607420aaa1\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alnylam-astrazeneca-evotec-astellas\/#Alnylam_Pharmaceuticals_has_released_the_Phase_III_results_of_the_clinical_trial_ILLUMINATE-A_evaluating_lumasiran_for_Primary_Hyperoxaluria_Type_1\" >Alnylam Pharmaceuticals has released the Phase III results of the clinical trial ILLUMINATE-A evaluating lumasiran for Primary Hyperoxaluria Type 1<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alnylam-astrazeneca-evotec-astellas\/#AstraZenecas_Calquence_acalabrutinib_%E2%80%93_an_oncology_drug_was_found_to_be_effective_in_treating_COVID-19\" >AstraZeneca&#8217;s Calquence (acalabrutinib) \u2013 an oncology drug was found to be effective in treating COVID-19<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alnylam-astrazeneca-evotec-astellas\/#Astellas_Pharma_has_released_the_results_of_its_Phase_III_DOLOMITES_trial_comparing_its_roxadustat_with_Amgens_Aranesp_darbepoetin_alfa_for_anemia_in_non-dialysis_dependent_NDD_due_to_stage_3-5_chronic_kidney_disease_CKD\" >Astellas Pharma has released the results of its Phase III DOLOMITES trial comparing its roxadustat with Amgen&#8217;s Aranesp (darbepoetin alfa) for anemia in non-dialysis dependent (NDD) due to stage 3-5 chronic kidney disease (CKD)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alnylam-astrazeneca-evotec-astellas\/#Evotec_SE_has_announced_a_partnership_between_its_subsidiary_Just_%E2%80%93_Evotec_Biologics_with_Advanced_BioScience_Laboratories_ABL_for_designing_broadly_neutralizing_antibody_against_HIV\" >Evotec SE has announced a partnership between its subsidiary Just &#8211; Evotec Biologics with Advanced BioScience Laboratories (ABL) for designing broadly neutralizing antibody against HIV<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Alnylam_Pharmaceuticals_has_released_the_Phase_III_results_of_the_clinical_trial_ILLUMINATE-A_evaluating_lumasiran_for_Primary_Hyperoxaluria_Type_1\"><\/span><strong>Alnylam Pharmaceuticals has released the Phase III results of the clinical trial ILLUMINATE-A evaluating lumasiran for Primary Hyperoxaluria Type 1<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-hyperoxaluria-market\">Primary Hyperoxaluria<\/a> Type 1 (PH1)<strong> <\/strong>is a rare disorder that affects kidneys due to an excess buildup of oxalate, which in normal cases is filtered through the kidneys and excreted in the urine.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Alnylam&#8217;s Lumasiran is an experimental RNA interference (RNAi) therapy that targets hydroxy acid oxidase 1 (HAO1) responsible for the production of the glycolate oxidase (GO), thus blocking the production of oxalate. The drug was able to hit all the primary endpoints and secondary endpoints with no reported serious side effects besides mild injection site reactions.&nbsp;<\/p>\n\n\n\n<p>Results of the clinical trial were presented at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) International Congress.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"AstraZenecas_Calquence_acalabrutinib_%E2%80%93_an_oncology_drug_was_found_to_be_effective_in_treating_COVID-19\"><\/span><strong>AstraZeneca&#8217;s Calquence (acalabrutinib) \u2013 an oncology drug was found to be effective in treating COVID-19<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Researchers at The U.S. Oncology Network found AstraZeneca&#8217;s oncology drug, Calquence (acalabrutinib) beneficial in treating a smaller section of patients suffering from <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\"><strong>novel coronavirus<\/strong><\/a> infections.&nbsp;<\/p>\n\n\n\n<p>The preliminary research showed that the drug &#8211; Calquence, a Bruton Tyrosine Kinase (BTK) Inhibitor &#8211; was able to improve oxygenation of the patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-respiratory-distress-syndrome-ards-market\"><strong>acute respiratory distress syndrome (ARDS)<\/strong><\/a> due to <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\"><strong>COVID-19<\/strong><\/a>, with no observed toxicities attributable to acalabrutinib, including those listed on the product&#8217;s important safety information, such as cardiac arrhythmia, bleeding, diarrhea or opportunistic infection.<\/p>\n\n\n\n<p>Calquence is available in the market as an approved therapy for the treatment of adult patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-lymphocytic-leukemia-cll-market\">chronic lymphocytic leukemia (CLL)<\/a> or <a href=\"https:\/\/www.delveinsight.com\/report-store\/small-lymphocytic-lymphoma-market\">small lymphocytic lymphoma (SLL)<\/a>, relapsed or refractory <a href=\"https:\/\/www.delveinsight.com\/report-store\/mantle-cell-lymphoma-market\">mantle cell lymphoma (MCL)<\/a>.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Astellas_Pharma_has_released_the_results_of_its_Phase_III_DOLOMITES_trial_comparing_its_roxadustat_with_Amgens_Aranesp_darbepoetin_alfa_for_anemia_in_non-dialysis_dependent_NDD_due_to_stage_3-5_chronic_kidney_disease_CKD\"><\/span><strong>Astellas Pharma has released the results of its Phase III DOLOMITES trial comparing its roxadustat with Amgen&#8217;s Aranesp (darbepoetin alfa) for anemia in non-dialysis dependent (NDD) due to stage 3-5 chronic kidney disease (CKD)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The results demonstrated Roxadustat was belt meet the primary endpoint and was proved non-inferior to Aranesp in hemoglobin levels during the first 24 weeks of treatment. Furthermore, the drug successfully hit several secondary endpoints with overall safety comparable to that of Aranesp.<\/p>\n\n\n\n<p>Roxadustat is a first-in-class oral inhibitor of <a href=\"https:\/\/www.delveinsight.com\/report-store\/hypoxia-inducible-factor-prolyl-4-hydroxylase-hif-ph-inhibitor-pipeline-insight\">hypoxia-inductible factor (HIF) prolyl hydroxylase<\/a> (PH). It increases the hemoglobin level by stimulating the body&#8217;s natural protective response to decreased blood oxygen levels.&nbsp;<\/p>\n\n\n\n<p>The results were presented the data at an oral presentation of the 57th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Evotec_SE_has_announced_a_partnership_between_its_subsidiary_Just_%E2%80%93_Evotec_Biologics_with_Advanced_BioScience_Laboratories_ABL_for_designing_broadly_neutralizing_antibody_against_HIV\"><\/span><strong>Evotec SE has announced a partnership between its subsidiary Just &#8211; Evotec Biologics with Advanced BioScience Laboratories (ABL) for designing broadly neutralizing antibody against HIV<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The whole project has been funded with Federal funds under a USD 318.5 M contract from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services.&nbsp;<\/p>\n\n\n\n<p>Under the terms of the agreement, Just &#8211; Evotec Biologics will be responsible for developing a highly efficient manufacturing process required for the production of Phase I cGMP clinical supply of a broadly neutralizing antibody (&#8220;bnAb&#8221;) against <a href=\"https:\/\/www.delveinsight.com\/report-store\/hiv-associated-lipodystrophy-market\">HIV<\/a>. Moreover, the company will also produce a suitably scaled production run under cGMP conditions acceptable for human clinical trials, a product formulation suitable for clinical infusion and provide assay development and release and stability testing services.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alnylam Pharmaceuticals has released the Phase III results of the clinical trial ILLUMINATE-A evaluating lumasiran for Primary Hyperoxaluria Type 1 Primary Hyperoxaluria Type 1 (PH1) is a rare disorder that affects kidneys due to an excess buildup of oxalate, which in normal cases is filtered through the kidneys and excreted in the urine.&nbsp;&nbsp; Alnylam&#8217;s Lumasiran [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9524,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":2,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[12149,18441,1482,831,18439,12146,2085,96,18438,18442,10830,18440,349,639,18437,18026,18443],"industry":[17225],"therapeutic_areas":[17231,17228,17243],"class_list":["post-9521","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-acute-respiratory-distress-syndrome-2","tag-advanced-bioscience-laboratories","tag-alnylam-pharmaceuticals","tag-amgen","tag-aranesp","tag-ards","tag-astellas-pharma","tag-astrazeneca","tag-calquence","tag-chronic-lymphocytic-leukemia","tag-covid-19","tag-evotec-se","tag-latest-pharma-news","tag-pharma-news","tag-primary-hyperoxaluria-type-1","tag-relapsed-or-refractory-mantle-cell-lymphoma","tag-small-lymphocytic-lymphoma","industry-pharmaceutical","therapeutic_areas-infectious-diseases","therapeutic_areas-oncology","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Lumasiran&#039;s results; AZ\u2019s Calquence; Astellas&#039;s Roxadustat; Evotec&#039;s pact<\/title>\n<meta name=\"description\" content=\"Alnylam Pharmaceuticals has released the Phase III results of the clinical trial ILLUMINATE-A evaluating lumasiran for Primary Hyperoxaluria Type 1. Alnyl..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alnylam-astrazeneca-evotec-astellas\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lumasiran&#039;s results; AZ\u2019s Calquence; Astellas&#039;s Roxadustat; Evotec&#039;s pact\" \/>\n<meta property=\"og:description\" content=\"Alnylam Pharmaceuticals has released the Phase III results of the clinical trial ILLUMINATE-A evaluating lumasiran for Primary Hyperoxaluria Type 1. Alnyl..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alnylam-astrazeneca-evotec-astellas\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-09T12:07:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T05:38:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/09173307\/news-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lumasiran's results; AZ\u2019s Calquence; Astellas's Roxadustat; Evotec's pact","description":"Alnylam Pharmaceuticals has released the Phase III results of the clinical trial ILLUMINATE-A evaluating lumasiran for Primary Hyperoxaluria Type 1. Alnyl..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alnylam-astrazeneca-evotec-astellas","og_locale":"en_US","og_type":"article","og_title":"Lumasiran's results; AZ\u2019s Calquence; Astellas's Roxadustat; Evotec's pact","og_description":"Alnylam Pharmaceuticals has released the Phase III results of the clinical trial ILLUMINATE-A evaluating lumasiran for Primary Hyperoxaluria Type 1. Alnyl..","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alnylam-astrazeneca-evotec-astellas","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-06-09T12:07:27+00:00","article_modified_time":"2023-06-14T05:38:02+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/09173307\/news-2.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alnylam-astrazeneca-evotec-astellas","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alnylam-astrazeneca-evotec-astellas","name":"Lumasiran's results; AZ\u2019s Calquence; Astellas's Roxadustat; Evotec's pact","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alnylam-astrazeneca-evotec-astellas#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alnylam-astrazeneca-evotec-astellas#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/09173307\/news-2.jpg","datePublished":"2020-06-09T12:07:27+00:00","dateModified":"2023-06-14T05:38:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Alnylam Pharmaceuticals has released the Phase III results of the clinical trial ILLUMINATE-A evaluating lumasiran for Primary Hyperoxaluria Type 1. Alnyl..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alnylam-astrazeneca-evotec-astellas"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alnylam-astrazeneca-evotec-astellas#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/09173307\/news-2.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/09173307\/news-2.jpg","width":772,"height":482,"caption":"pharma-news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/09173307\/news-2-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">acute respiratory distress syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Advanced BioScience Laboratories<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alnylam Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amgen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Aranesp<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ARDS<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Astellas Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Calquence<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chronic Lymphocytic Leukemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID-19<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Evotec SE<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Primary Hyperoxaluria Type 1<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Relapsed Or Refractory Mantle Cell Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Small Lymphocytic Lymphoma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">acute respiratory distress syndrome<\/span>","<span class=\"advgb-post-tax-term\">Advanced BioScience Laboratories<\/span>","<span class=\"advgb-post-tax-term\">Alnylam Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Amgen<\/span>","<span class=\"advgb-post-tax-term\">Aranesp<\/span>","<span class=\"advgb-post-tax-term\">ARDS<\/span>","<span class=\"advgb-post-tax-term\">Astellas Pharma<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Calquence<\/span>","<span class=\"advgb-post-tax-term\">Chronic Lymphocytic Leukemia<\/span>","<span class=\"advgb-post-tax-term\">COVID-19<\/span>","<span class=\"advgb-post-tax-term\">Evotec SE<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Primary Hyperoxaluria Type 1<\/span>","<span class=\"advgb-post-tax-term\">Relapsed Or Refractory Mantle Cell Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Small Lymphocytic Lymphoma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jun 9, 2020","modified":"Updated on Jun 14, 2023"},"absolute_dates_time":{"created":"Posted on Jun 9, 2020 5:37 pm","modified":"Updated on Jun 14, 2023 11:08 am"},"featured_img_caption":"pharma-news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9521"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9521\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/9524"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9521"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9521"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}